Results 41 to 50 of about 22,483 (254)

Spontaneous poisoning of cattle by onion (Allium cepa) in Brazil [PDF]

Pesquisa Veterinária Brasileira
: The state of Santa Catarina is the largest national producer of onions. The consumption of onion (Allium cepa) by domestic animals can cause hemolytic anemia and hyperhemoglobinemia of Heinz bodies in erythrocytes.
Gustavo Felipe G.P. Hugen, Daiane Ogliari, Nathalia S. Wicpolt, Elaine Melchioretto, Sandra D. Traverso, Claudia Wisser, Deise Hemckmeier, Aldo Gava   +7 more
doaj   +1 more source

Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Haematologica, 2020
Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab.
R. Brodsky, R. D. de Latour, S. Rottinghaus, A. Röth, A. Risitano, I. Weitz, P. Hillmen, J. Maciejewski, J. Szer, J. W. Lee, A. Kulasekararaj, L. Volles, A. Damokosh, S. Ortiz, L. Shafner, Peng Liu, A. Hill, H. Schrezenmeier   +17 more
semanticscholar   +1 more source

Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia

Leukemia, 2021
In this large single-centre study, we report high prevalence (25%) of, small (
B. Fattizzo, R. Ireland, A. Dunlop, D. Yallop, S. Kassam, Joanna Large, Shreyans Gandhi, P. Muus, Charles Manogaran, Katy Sanchez, D. Consonni, W. Barcellini, G. Mufti, J. Marsh, A. Kulasekararaj   +14 more
semanticscholar   +1 more source

Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria

Turkish Journal of Hematology, 2013
OBJECTIVE: The responses of 32 patients with paroxysmal nocturnal hemoglobinuria (PNH) were assessed after the patients were put on various combinations of danazol, prednisolone, and cyclosporine.
Kanjaksha Ghosh, Manisha Madkaikar, Maya Gupta, Farah Jijina   +3 more
doaj   +1 more source

Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real‐world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry

European Journal of Haematology, 2022
The effects of eculizumab treatment in paroxysmal nocturnal hemoglobinuria (PNH) patients with or without high‐disease activity (HDA), defined by LDH ≥ 1.5 × ULN and history of major adverse vascular events (MAVEs; including thrombotic events [TEs ...
B. Höchsmann, F. Sicre de Fontbrune, J. W. Lee, A. Kulagin, P. Hillmen, A. Wilson, J. Marantz, H. Schrezenmeier   +7 more
semanticscholar   +1 more source

Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.

Blood, 2020
Acquired aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are pathogenically related non-malignant bone marrow failure disorders linked to T-cell mediated autoimmunity and associated with an increased risk of secondary myelodysplastic ...
Lova Sun, D. Babushok
semanticscholar   +1 more source

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria

Blood, 2021
Complement has emerged as a likely driver of the immune response and end-organ damage in COVID-19. In patients with severe disease, deposition of terminal complement and microthrombosis have been observed in the lung, skin, kidney, and heart.
G. Gerber, Xuan Yuan, Jia Yu, Benjamin A. Y. Cher, Evan M. Braunstein, Shruti Chaturvedi, R. Brodsky   +6 more
semanticscholar   +1 more source

Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Haematologica, 2014
Paroxysmal nocturnal hemoglobinuria is a rare, acquired disease associated with hemolytic anemia, bone marrow failure, thrombosis, and, frequently, poor quality of life.
Hubert Schrezenmeier, Petra Muus, Gérard Socié, Jeffrey Szer, Alvaro Urbano-Ispizua, Jaroslaw P. Maciejewski, Robert A. Brodsky, Monica Bessler, Yuzuru Kanakura, Wendell Rosse, Gus Khursigara, Camille Bedrosian, Peter Hillmen   +12 more
doaj   +1 more source

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

Frontiers in Immunology, 2019
The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed,
A. Risitano, S. Marotta, P. Ricci, L. Marano, Camilla Frieri, F. Cacace, M. Sica, A. Kulasekararaj, R. Calado, P. Scheinberg, R. Notaro, R. Peffault de Latour   +11 more
semanticscholar   +1 more source

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab

American journal of hematology/oncology, 2020
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, life‐threatening hematologic disease characterized by chronic complement‐mediated hemolysis and thrombosis.
Carlos M. de Castro, F. Grossi, I. Weitz, J. Maciejewski, Vivek Sharma, E. Roman, R. Brodsky, L. Tan, Carl Di casoli, D. El Mehdi, Pascal Deschatelets, C. Francois   +11 more
semanticscholar   +1 more source